Evofem Biosciences, Inc. (EVFM)
0.0111
0.00 (0.00%)
USD |
OTCM |
Dec 15, 10:08
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.406M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 23.71% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.9989 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.7431 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA. |
| URL | http://www.evofem.com |
| Investor Relations URL | http://investors.neothetics.com/phoenix.zhtml?c=253672&p=irol-IRHome |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 02, 2018 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA. |
| URL | http://www.evofem.com |
| Investor Relations URL | http://investors.neothetics.com/phoenix.zhtml?c=253672&p=irol-IRHome |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 02, 2018 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |